Recruiting

Patient Decision Aid

Sponsor:

University of Colorado, Denver

Code:

NCT05900375

Conditions

Ureteropelvic Junction Obstruction

Ureteropelvic Junction; Obstruction, Congenital

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Parent Decision Aid

Study Details

Brief summary:

Ureteropelvic junction obstruction (UPJO) is the most common etiology of high-grade hydronephrosis, affecting approximately 4,000-10,000 infants annually in the U.S. The goal of surgical treatment of UPJO is to minimize the risk of kidney damage associated with obstruction, which may occur in 30-60% of infants with high-grade hydronephrosis.1-However, the benefit of early surgery compared to observation and potential later surgery to preserve kidney function has not been well-defined. Consequently, surgeons differ on whether to initially treat with surgery or observation, with surgical rates in the first year of life varying from 15-50% across surgical practices. These variations are important to understand, as the decision for early surgery is not without risk. Prior studies suggest that infants treated surgically are at higher risk for readmission and reoperation. Early surgery also raises concerns about neurodevelopmental effects of anesthetic exposure.

To address this gap, the purpose of this pilot test is to develop a patient decision aid (PtDA) tool and pilot test its effect on parental understanding and engagement in the decision-making process at Children's Hospital Colorado. The proposed pilot is a necessary first step in preparation for a future multicenter hybrid effectiveness-implementation trial. This work will also be used to support future studies evaluating the impact of a PtDA on surgical variations and treatment outcomes in patients with UPJO and other complex congenital urologic anomalies.

Conditions

Ureteropelvic Junction Obstruction

Ureteropelvic Junction; Obstruction, Congenital

Study ID

NCT05900375

Start date

Jan 21, 2023

Status verified date

May, 2024

Completion date

Dec 31, 2025

Anticipated

Primary completion date

Dec 31, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria (all of following are needed):

  • parents (age 18-89 years) of children age 30 days - 2 years
  • child is presenting for consultation for SFU grade 3-4 Hydronephrosis at Children's Hospital Colorado
  • parents/child presenting at Urology appointment where a MAG 3 is performed or has recently been performed.

Exclusion Criteria:

  • does not meet age parameters
  • does not have a child with a UPJO

Study Design

Enrollment

100 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Health Services Research

Interventions and Outcome Measures

Arms

experimental: Intervention Arm - Receipt of PtDA

Parents in the intervention arm will receive a paper decision aid prior to meeting with their health care professional about their child's treatment options for UPJO.

no intervention: Control - Usual Care

Parents in the control arm will not receive a paper decision aid and instead will just receive usual care about their child's treatment options for UPJO.

Interventions

Parent Decision Aid

A paper parent decision aid in color will be provided to all patients at the time of their appointment and will aid in discussion with health care professionals.

Primary outcome measure

  • Differences in the SDM-Q9 scores between arms [ Time Frame: through study completion, an average of 1 year ]

Central Contacts and Locations

Central contacts

Locations

Children's Hospital Colorado

Recruiting

Aurora, Colorado, United States, 80045

Contacts

Principal Investigator:

Vijaya Vemulakonda, MD, JD

More Information

Sponsor

University of Colorado, Denver

Last update posted

May 23, 2024

Last verified

May, 2024

Keywords

  • shared decision making
  • pragmatic trial
  • congenital kidney anomaly

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Colorado, Denver on 2024-05-23.